Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VL-2397 vs standard first-line therapy for invasive aspergillosis
2017-003435-11Phase 2Terminated
- Sponsor
- Vical Incorporated
- Start
- Feb 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of GR-2397 in invasive aspergillosis (IA) and neuroaspergillosis (2 arms), sponsored by Vical Incorporated. Primary endpoint: All-cause mortality at 4 weeks. Started Feb 2018; status: terminated.
02
Drugs
GR-2397
03
Conditions
invasive aspergillosis (IA)neuroaspergillosis
Beyond the preview
Go deeper on 2017-003435-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003435-11.